Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years or older~* Japanese male or female~* Non- valvular atrial fibrillation documented by ECG~* Patients with a risk of stroke and non-CNS systemic embolism~Exclusion Criteria:~* Significant mitral stenosis~* Patients in whom anticoagulants are contraindicated

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
- Warfarin (Type: ACTIVE_COMPARATOR): Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).